TAM
WST icon

Trillium Asset Management’s West Pharmaceutical WST Stock Holding History

Trillium Asset Management’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,518
Closed -$497K – 236
2024
Q4 		$497K Sell
1,518
-784
-34% -$247K 0.01% 188
2024
Q3 		$691K Sell
2,302
-16,713
-88% -$5.12M 0.02% 179
2024
Q2 		$6.26M Sell
19,015
-341
-2% -$121K 0.16% 131
2024
Q1 		$7.66M Sell
19,356
-23,815
-55% -$8.81M 0.19% 111
2023
Q4 		$15.2M Sell
43,171
-21,734
-33% -$7.69M 0.41% 77
2023
Q3 		$24.4M Sell
64,905
-10,049
-13% -$3.89M 0.73% 45
2023
Q2 		$28.7M Sell
74,954
-1,165
-2% -$416K 0.8% 42
2023
Q1 		$27.4M Buy
76,119
+3,282
+5% +$959K 0.8% 47
2022
Q4 		$17.1M Buy
72,837
+29,752
+69% +$7.05M 0.53% 74
2022
Q3 		$10.6M Sell
43,085
-7,329
-15% -$2.23M 0.35% 87
2022
Q2 		$15.5M Buy
50,414
+4,502
+10% +$1.46M 0.47% 75
2022
Q1 		$18.9M Sell
45,912
-3,086
-6% -$1.21M 0.5% 74
2021
Q4 		$23M Buy
48,998
+1,787
+4% +$769K 0.54% 67
2021
Q3 		$20M Buy
47,211
+19,156
+68% +$8.08M 0.53% 72
2021
Q2 		$10M Buy
28,055
+3,275
+13% +$1.08M 0.28% 95
2021
Q1 		$6.98M Buy
24,780
+16,135
+187% +$4.62M 0.22% 104
2020
Q4 		$2.45M Sell
8,645
-4,823
-36% -$1.35M 0.09% 138
2020
Q3 		$3.7M Sell
13,468
-13,028
-49% -$3.45M 0.16% 108
2020
Q2 		$6.02M Sell
26,496
-481
-2% -$94.5K 0.26% 96
2020
Q1 		$4.11M Buy
26,977
+857
+3% +$132K 0.22% 109
2019
Q4 		$3.93M Buy
26,120
+227
+0.9% +$33.1K 0.17% 127
2019
Q3 		$3.67M Buy
25,893
+3,762
+17% +$518K 0.17% 127
2019
Q2 		$2.77M Buy
22,131
+2,698
+14% +$318K 0.13% 145
2019
Q1 		$2.14M Buy
19,433
+7,626
+65% +$793K 0.11% 153
2018
Q4 		$1.16M Buy
11,807
+461
+4% +$50K 0.07% 176
2018
Q3 		$1.4M Buy
11,346
+185
+2% +$20.7K 0.07% 174
2018
Q2 		$1.11M Buy
11,161
+257
+2% +$23.7K 0.06% 182
2018
Q1 		$963K Buy
+10,904
New +$1.02M 0.05% 183

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DCP
Durable Capital Partners Bethesda, Maryland $10.3B AUM 29.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Trillium Asset Management's WST Position: Q1 2025 in Review

Trillium Asset Management sold out of West Pharmaceutical (WST) in Q1 2025, closing a stake of 1,518 shares — an estimated $497K sold.

Trillium Asset Management first reported a position in WST in Q1 2018 and held it in 28 quarters. The position peaked at $28.7M in Q2 2023. 715 funds tracked by Wall St. Rank hold WST as of Q1 2025.

  • Trillium Asset Management reported no remaining West Pharmaceutical position as of Q1 2025 after selling out during the quarter.
  • Trillium Asset Management sold 1,518 West Pharmaceutical shares in Q1 2025, an estimated $497K.
  • Trillium Asset Management first reported a position in West Pharmaceutical in Q1 2018 and held it in 28 quarters.
  • Trillium Asset Management's West Pharmaceutical position peaked at $28.7M in Q2 2023.
  • 715 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2025.

Based on Trillium Asset Management's 13F filing for Q1 2025, filed 13 May 2025.